Immunic, Inc. (NASDAQ:IMUX – Get Rating) Chairman Duane Nash purchased 10,000 shares of the stock in a transaction on Thursday, May 12th. The shares were purchased at an average cost of $5.03 per share, with a total value of $50,300.00. Following the transaction, the chairman now owns 22,032 shares in the company, valued at approximately $110,820.96. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of IMUX stock opened at $5.85 on Friday. The stock has a market cap of $178.66 million, a PE ratio of -1.87 and a beta of 1.99. The business has a 50-day simple moving average of $9.55 and a 200-day simple moving average of $10.18. Immunic, Inc. has a 52-week low of $4.96 and a 52-week high of $15.12.
Immunic (NASDAQ:IMUX – Get Rating) last issued its quarterly earnings data on Thursday, February 24th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.08). During the same quarter last year, the business earned ($0.46) earnings per share. As a group, research analysts expect that Immunic, Inc. will post -3.2 EPS for the current year.
Several hedge funds have recently modified their holdings of the company. Silverarc Capital Management LLC acquired a new position in shares of Immunic in the 1st quarter valued at about $774,000. Northern Trust Corp raised its holdings in Immunic by 3.0% in the 1st quarter. Northern Trust Corp now owns 188,148 shares of the company’s stock worth $2,126,000 after purchasing an additional 5,553 shares during the period. Parkman Healthcare Partners LLC raised its holdings in Immunic by 11.8% in the 1st quarter. Parkman Healthcare Partners LLC now owns 1,089,251 shares of the company’s stock worth $12,309,000 after purchasing an additional 115,068 shares during the period. DLD Asset Management LP acquired a new position in Immunic in the 1st quarter worth about $565,000. Finally, Vanguard Group Inc. raised its holdings in Immunic by 6.1% in the 1st quarter. Vanguard Group Inc. now owns 956,697 shares of the company’s stock worth $10,811,000 after purchasing an additional 54,867 shares during the period. 49.03% of the stock is owned by institutional investors and hedge funds.
Immunic Company Profile (Get Rating)
Immunic, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.
- Get a free copy of the StockNews.com research report on Immunic (IMUX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.